Literature DB >> 21343951

Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model.

Jessica L Mester1, Amanda K Tilot, Lisa A Rybicki, Thomas W Frazier, Charis Eng.   

Abstract

PTEN Hamartoma Tumour Syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), and other conditions resulting from germline mutation of the PTEN tumour suppressor gene. Although macrocephaly, presumably due to megencephaly, is found in both CS and BRRS, the prevalence and degree have not been formally assessed in PHTS. We evaluated head size in a prospective nested series of 181 patients found to have pathogenic germline PTEN mutations. Clinical data including occipital-frontal circumference (OFC) measurement were requested for all participants. Macrocephaly was present in 94% of 161 evaluable PHTS individuals. In patients ≤ 18 years, mean OFC was +4.89 standard deviations (SD) above the population mean with no difference between genders (P = 0.7). Among patients >18 years, average OFC was 60.0 cm in females and 62.8 cm in males (P < 0.0001). To systematically determine whether macrocephaly was due to megencephaly, we examined Pten(M3M4) missense mutant mice generated and maintained on mixed backgrounds. Mice were killed at various ages, brains were dissected out and weighed. Average brain weight for Pten(M3M4) homozygous mice (N = 15) was 1.02 g compared with 0.57 g for heterozygous mice (N = 29) and 0.49 g for wild-type littermates (N = 24) (P < 0.0001). Macrocephaly, secondary to megencephaly, is an important component of PHTS and more prevalent than previously appreciated. Patients with PHTS have increased risks for breast and thyroid cancers, and early diagnosis is key to initiating timely screening to reduce patient morbidity and mortality. Clinicians should consider germline PTEN testing at an early point in the diagnostic work-up for patients with extreme macrocephaly.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21343951      PMCID: PMC3137495          DOI: 10.1038/ejhg.2011.20

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  27 in total

1.  Standards for selected anthropometric measurements in males with the fragile X syndrome.

Authors:  M G Butler; A Brunschwig; L K Miller; R J Hagerman
Journal:  Pediatrics       Date:  1992-06       Impact factor: 7.124

2.  Growth in North American white children with neurofibromatosis 1 (NF1).

Authors:  J Szudek; P Birch; J M Friedman
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

3.  Head circumference from birth to eighteen years. Practical composite international and interracial graphs.

Authors:  G Nellhaus
Journal:  Pediatrics       Date:  1968-01       Impact factor: 7.124

4.  A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.

Authors:  Min-Han Tan; Jessica Mester; Charissa Peterson; Yiran Yang; Jin-Lian Chen; Lisa A Rybicki; Kresimira Milas; Holly Pederson; Berna Remzi; Mohammed S Orloff; Charis Eng
Journal:  Am J Hum Genet       Date:  2010-12-30       Impact factor: 11.025

5.  Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults.

Authors:  Xiao-Ping Zhou; Deborah J Marsh; Carl D Morrison; Abhik R Chaudhury; Marius Maxwell; Guido Reifenberger; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-10-17       Impact factor: 11.025

6.  Lhermitte-Duclos disease and Cowden disease: a single phakomatosis.

Authors:  G W Padberg; J D Schot; G J Vielvoye; G T Bots; F C de Beer
Journal:  Ann Neurol       Date:  1991-05       Impact factor: 10.422

7.  Relationship between head circumference and height in normal adults and in the nevoid basal cell carcinoma syndrome and neurofibromatosis type I.

Authors:  S J Bale; C I Amos; D M Parry; A E Bale
Journal:  Am J Med Genet       Date:  1991-08-01

Review 8.  Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis.

Authors:  Charis Eng
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

Review 9.  Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome.

Authors:  R Pilarski; C Eng
Journal:  J Med Genet       Date:  2004-05       Impact factor: 6.318

10.  The Cowden syndrome: a clinical and genetic study in 21 patients.

Authors:  T M Starink; J P van der Veen; F Arwert; L P de Waal; G G de Lange; J J Gille; A W Eriksson
Journal:  Clin Genet       Date:  1986-03       Impact factor: 4.438

View more
  42 in total

1.  A Saturation Mutagenesis Approach to Understanding PTEN Lipid Phosphatase Activity and Genotype-Phenotype Relationships.

Authors:  Taylor L Mighell; Sara Evans-Dutson; Brian J O'Roak
Journal:  Am J Hum Genet       Date:  2018-04-26       Impact factor: 11.025

Review 2.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

Review 3.  Genetic control of postnatal human brain growth.

Authors:  Laura I van Dyck; Eric M Morrow
Journal:  Curr Opin Neurol       Date:  2017-02       Impact factor: 5.710

4.  An Integrated Deep-Mutational-Scanning Approach Provides Clinical Insights on PTEN Genotype-Phenotype Relationships.

Authors:  Taylor L Mighell; Stetson Thacker; Eric Fombonne; Charis Eng; Brian J O'Roak
Journal:  Am J Hum Genet       Date:  2020-05-21       Impact factor: 11.025

5.  Bannayan-Riley-Ruvalcaba syndrome: MRI neuroimaging features in a series of 7 patients.

Authors:  R Bhargava; K J Au Yong; N Leonard
Journal:  AJNR Am J Neuroradiol       Date:  2013-08-01       Impact factor: 3.825

Review 6.  Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder.

Authors:  Amanda K Tilot; Thomas W Frazier; Charis Eng
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

7.  Conformational stability and catalytic activity of PTEN variants linked to cancers and autism spectrum disorders.

Authors:  Sean B Johnston; Ronald T Raines
Journal:  Biochemistry       Date:  2015-02-13       Impact factor: 3.162

8.  Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity.

Authors:  Xin He; Nicholas Arrotta; Deepa Radhakrishnan; Yu Wang; Todd Romigh; Charis Eng
Journal:  Cancer Res       Date:  2013-03-08       Impact factor: 12.701

9.  PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome.

Authors:  Xin He; Motoyasu Saji; Deepa Radhakrishnan; Todd Romigh; Joanne Ngeow; Qi Yu; Yu Wang; Matthew D Ringel; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-09-07       Impact factor: 5.958

10.  Sending Mixed Signals: The Expanding Role of Molecular Cascade Mutations in Malformations of Cortical Development and Epilepsy.

Authors:  Philip H Iffland; Peter B Crino
Journal:  Epilepsy Curr       Date:  2016 May-Jun       Impact factor: 7.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.